Carboxyl porphyrin-curcumin esterified conjugate as well as preparation method and application thereof

The carboxyporphyrin-curcumin esterification conjugates formed through Steglich esterification reaction solve the problem of poor curcumin bioavailability, enhance the porphyrin photodynamic efficacy, and achieve the dual anti-tumor effect of photodynamic and chemotherapy. Suitable for mass production.

CN119039304AActive Publication Date: 2024-11-29CENT SOUTH UNIV

Patent Information

Application Number
CN202411003779.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-29
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

In the prior art, the poor bioavailability and insufficient solubility of curcumin limit its enrichment and anti-cancer effects in tumor tissues. The coupling construction of porphyrin compounds and curcumin has not been reported, resulting in the therapeutic effect of photodynamic therapy. limit.

Method used

The carboxy group-containing porphyrin is coupled to the phenolic hydroxyl group of curcumin through Steglich esterification reaction to form a carboxyporphyrin-curcumin esterification conjugate, which utilizes the biodegradability of the ester bond and the targeted photosensitive of porphyrins It is de novo, enhances the enrichment and photodynamic efficacy of curcumin, and combines the efficacy of chemotherapy.

Benefits of technology

It improves the bioavailability of curcumin and tumor tissue enrichment, enhances the porphyrin photodynamic efficacy, realizes the dual anti-tumor effects of photodynamic and chemotherapy. It has a simple preparation method, low raw material cost, and is suitable for mass production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039304A_ABST
    Figure CN119039304A_ABST
Patent Text Reader

Abstract

The invention discloses a carboxyl porphyrin-curcumin esterified conjugate as well as a preparation method and application thereof, and belongs to the field of organic synthesis and biological medicine. A carboxyl-containing porphyrin photosensitizer, such as pyropheophorbide a, protoporphyrin, tetracarboxyl phenyl porphyrin and the like, is coupled with curcumin with anticancer activity in an esterification manner to obtain the carboxyl porphyrin-curcumin esterification conjugate, and the carboxyl porphyrin-curcumin esterification conjugate has double anticancer activity of photodynamic and chemotherapy, and can be used as an antitumor drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a carboxyl porphyrin-curcumin ester conjugate and a synthesis method thereof, and also relates to application of the carboxyl porphyrin-curcumin ester conjugate in preparing an anti-tumor agent for photodynamic therapy combined with chemotherapy, belonging to the technical field of drug synthesis. Background Art

[0002] Cancer, also known as malignant tumor, has a high incidence and mortality rate despite the great improvement in current medical standards. In addition to traditional surgery, chemotherapy, radiotherapy, targeted therapy and photodynamic therapy have also achieved certain results in the treatment of cancer.

[0003] Photodynamic therapy (PDT) is a new technology for treating cancer. It uses a specific wavelength to irradiate the lesion site, which can activate the photosensitive drug that selectively accumulates in the lesion tissue, generate highly biologically active singlet oxygen, produce cytotoxicity, and then kill the diseased cells, induce tumor cell apoptosis, and destroy the lesion. Compared with traditional therapies, PDT can accurately and effectively treat with fewer side effects.

[0004] As an effective photosensitizer, porphyrin compounds, whether chlorophyll a derivatives, hematoporphyrin derivatives or various chemically synthesized porphyrin photosensitizers, play a very important role in photodynamic therapy.

[0005] As a natural phenol, curcumin has anti-cancer therapeutic ability, and curcumin and other turmeric-derived products have been marked as safe products by the U.S. Food and Drug Administration (FDA). Curcumin has achieved therapeutic goals in the treatment of metabolic diseases, immune-related diseases and cancer due to its wide range of biological targets and almost no sequelae. However, the poor bioavailability and solubility of curcumin limit its clinical application.

[0006] However, up to now, there has been no report on the coupling of porphyrin compounds with curcumin to construct new anti-tumor drugs. Summary of the invention

[0007] In view of the defects of the prior art, the first object of the present invention is to provide a carboxyl porphyrin-curcumin ester conjugate, which uses porphyrin as a targeted photosensitizer and carries curcumin with anti-cancer activity. It can not only solve the technical problems such as poor bioavailability of curcumin and insufficient enrichment in tumor tissue, but also enhance the photodynamic efficacy of porphyrin, making it have the dual effects of photodynamic and chemotherapy.

[0008] The second object of the present invention is to provide a method for preparing a carboxyl porphyrin-curcumin ester conjugate, which is simple, has low raw material cost, and is conducive to mass production.

[0009] The third object of the present invention is to provide a carboxyl porphyrin-curcumin ester conjugate, which can be used as an anti-tumor drug to exert the dual effects of photodynamic therapy and chemotherapy.

[0010] In order to achieve the above technical objectives, the present invention provides a carboxyl porphyrin-curcumin ester conjugate having a chemical structure of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6:

[0011]

[0012]

[0013] Among them, R is selected from R1, R2, R3 and R4 are independently selected from H or and at least one of R1, R2, R3 and R4 is

[0014] The carboxyl porphyrin-curcumin ester conjugate of the present invention couples the carboxyl porphyrin with the property of a targeted photosensitizer and the curcumin with a chemotherapeutic effect through an ester bond. On the one hand, the ester bond is biodegradable, and when the conjugate reaches the target cell, it is easy to release the anticancer drug in time; on the other hand, the conjugate formed by coupling the two has an absorption peak in the Q segment of the ultraviolet visible light region, which is beneficial to photodynamic therapy for cancer. On the third hand, curcumin has poor utilization and is difficult to be enriched in tumor tissues. The above problems of curcumin can be solved by using the carboxyl porphyrin as a carrier.

[0015] The present invention also provides a method for preparing a carboxyl porphyrin-curcumin esterification conjugate, which comprises coupling a carboxyl porphyrin-like compound with a phenolic hydroxyl group of curcumin through a Steglich esterification reaction to obtain;

[0016] The carboxyl-containing porphyrin-like compound has a chemical structure of Formula 7, Formula 8, Formula 9, Formula 10, Formula 11 or Formula 12:

[0017]

[0018]

[0019]

[0020] As a preferred solution, the conditions of the Steglich esterification reaction are: using 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride as a condensation agent, using 4-dimethylaminopyridine as a catalyst, and reacting at 15 to 25° C. for 12 to 36 hours.

[0021] As a preferred solution, the Steglich esterification reaction uses chloroform solvent or a mixed solvent of tetrahydrofuran and chloroform.

[0022] As a preferred solution, the relative amount of the condensing agent added is 2 to 3 times the carboxyl content in the carboxyl-containing porphyrin-like compound.

[0023] As a preferred solution, the relative amount of the catalyst added is 0.4 to 0.6 times the carboxyl content in the carboxyl-containing porphyrin-like compound.

[0024] As a preferred embodiment, the relative amount of curcumin added is 2 to 3 times the carboxyl content of the carboxyl-containing porphyrinoid.

[0025] The present invention also provides an application of a carboxyl porphyrin-curcumin ester conjugate, which is used for preparing an anti-tumor agent for photodynamic therapy combined with chemotherapy.

[0026] The carboxyl-containing porphyrins of the present invention can be selected from monocarboxyl porphyrins, such as pyropheophorbide a and its ether derivatives, which are widely available and easy to obtain from organisms, or polycarboxyl porphyrin compounds, such as protoporphyrin, and synthetic tetracarboxylphenylporphyrin. Specific examples include chlorophyll a acid degradation products and its ether derivatives, heme derivatives, and synthetic carboxyl-containing porphyrin compounds, including but not limited to the following compounds:

[0027]

[0028] The present invention provides a method for synthesizing a carboxyl porphyrin-curcumin esterification conjugate: the carboxyl group in the porphyrin-like molecule is coupled with the phenolic hydroxyl group in the curcumin molecule through a Steglich esterification reaction, and the reaction formula is as follows (taking PPA as an example):

[0029]

[0030] The purification and separation method of the Steglich esterification reaction product of the present invention can be purified by rapid column chromatography, the volume ratio of the developing agent is: dichloromethane: methanol = 30-50:1, EDCI and DMAP in the product can be washed away by dilute hydrochloric acid and ultrapure water, and residual curcumin can be washed away by ethanol.

[0031] The synthetic route of the esterified conjugate of the monocarboxyl-containing porphyrin-like compound and the polycarboxyl-containing porphyrin-like compound with curcumin is as follows:

[0032]

[0033] The specific steps for preparing the carboxyl-containing porphyrin and curcumin esterification conjugate of the present invention are as follows:

[0034] Dissolve or ultrasonically disperse the carboxyl-containing porphyrin-like substance in chloroform, add 2.5 times the amount of carboxyl substance EDCI, 0.5 times the amount of DMAP and 2.5 times the amount of curcumin, stir and react at room temperature in the dark for 24 hours, and add methanol or ethanol to react the residual active intermediates after the reaction. Spin dry the solvent, wash the crude product with dilute hydrochloric acid and water to remove the residual EDCI and DMAP, and wash the excess curcumin with ethanol. After the filter cake is dried, use dichloromethane: methanol = 35: 1 (volume ratio) silica gel column chromatography, collect the chromatographic band with red fluorescence, and you can get a high-purity esterification coupling product of porphyrin and curcumin.

[0035] The present invention selects chloroform as a solvent and EDCI as a dehydration condensation agent. Although a polycarboxyl porphyrin compound, such as protoporphyrin, is insoluble in chloroform, a one-pot method can still be used to obtain a 35% to 50% yield of esterification products of carboxyl porphyrin monosubstituted and disubstituted by curcumin, and the product is easy to separate and purify. Since EDCI is insoluble in tetrahydrofuran (THF), if N, N'-dicyclohexylcarbodiimide (DCC) and THF are combined, the carboxyl group is easily rearranged and loses activity at room temperature after being rapidly activated by DCC due to the poor nucleophilic attack ability of the phenolic hydroxyl group, resulting in a complex reaction system, especially the esterification of the polycarboxyl porphyrin compound and curcumin, which cannot obtain an ideal product, and unreacted DCC is difficult to remove, which increases the difficulty of separation and purification.

[0036] The principle of the Steglich esterification reaction of carboxyl-containing porphyrin compounds and curcumin under different condensation agents (EDCI and DCC) is as follows:

[0037]

[0038] The present invention uses carboxyl-containing porphyrin as a targeted photosensitizer and curcumin as a chemotherapeutic drug, and couples them through an esterification reaction. The obtained compound has an absorption peak in the Q segment of the ultraviolet-visible light region and can be used as a drug for photodynamic therapy of cancer.

[0039] The molecular structure of the most representative carboxyl porphyrin-curcumin ester conjugate of the present invention is as follows:

[0040]

[0041] Compared with the prior art, the technical solution of the present invention has the following beneficial technical effects:

[0042] The carboxyl porphyrin-curcumin ester conjugate of the present invention uses porphyrin as a targeted photosensitizer and carries curcumin with anti-cancer activity, which can not only solve the technical problems of poor bioavailability of curcumin and insufficient enrichment in tumor tissue, but also enhance the photodynamic efficacy of porphyrin, making it have the dual effects of photodynamic and chemotherapy.

[0043] The ester bond of the carboxyl porphyrin-curcumin esterification conjugate of the present invention is biodegradable. When the conjugate reaches the target cell, it is easy to release the anticancer drug in time, thereby improving the utilization rate of curcumin.

[0044] The preparation method of the carboxyl porphyrin-curcumin esterification conjugate of the present invention is simple, the raw material cost is low, and it is conducive to batch production.

[0045] The carboxyl porphyrin-curcumin ester conjugate of the present invention is used as an anti-tumor drug and can exert the dual effects of photodynamic therapy and chemotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 This is the nuclear magnetic resonance hydrogen spectrum (1H-NMR 400MHz, CDCl3) of the esterified conjugate of pyropheophorbide a (PPA) and curcumin (Curcumin) PPA-Curcumin.

[0047] Figure 2 PPA-Curcumin mass spectrometry detection diagram (MSI + ).

[0048] Figure 3 This is a comparison chart of infrared absorption spectra of PPA, Curcumin and PPA-Curcumin infrared spectra.

[0049] Figure 4 The mass spectrometry detection diagram (MSI) of the esterification coupling of protoporphyrin (PPIX) and curcumin (Curcumin) + ).

[0050] Figure 5 This is the hydrogen nuclear magnetic resonance spectrum (1H-NMR 400 MHz, CDCl3) of the esterification product of protoporphyrin and curcumin (compound IIPPIX-CE).

[0051] Figure 6 The PPIX-CE pure mass spectrum detection diagram (MSI + ).

[0052] Figure 7 The UV-visible absorption spectra of several typical carboxyl porphyrin-curcumin ester conjugates of the present invention are shown in FIG.

[0053] Figure 8 Fluorescence imaging for ROS detection of PPA-Curcumin and its control.

[0054] Fig. 9 This is a graph showing the anti-melanoma activity test of PPA-Curcumin and its control substance (cell live / dead staining analysis). DETAILED DESCRIPTION

[0055] In order to make the scheme of the present invention more specific and clear, representative specific embodiment cases are selected below for further explanation.

[0056] Example 1

[0057] Preparation of esterified conjugates of monocarboxyporphyrin and curcumin:

[0058] Preparation of pyropheophorbide a (PPA) and curcumin (Curcumin) esterification conjugate (PPA-Curcumin):

[0059] After purging the reaction flask with argon, add PPA 54 mg (0.1 mmol), curcumin 92 mg (0.25 mmol), EDCI 48 mg (0.25 mmol), DMAP 6 mg (0.05 mmol), add chloroform 10 mL, and react at room temperature in the dark for about 24 hours. The solvent is evaporated under reduced pressure to obtain a crude product. The crude product is washed with 1% dilute hydrochloric acid and distilled water to remove residual DMAP and EDCI, and then washed with ethanol to remove unreacted curcumin. After the filter cake is dried, silica gel column chromatography is performed with a developing solvent volume ratio of dichloromethane: methanol = 35:1 to obtain 56.2 mg of PPA-Curcumin esterification product with a yield of 63.5%.

[0060] PPA-Curcumin molecular structure characterization: 1H-NMR (400MHz, CDCl3, ppm, Figure 1 )δ9.48 (s, 1H), 9.38 (s, 1H), 8.58 (s, 1H), 7.97-8.04 (dd, 1H), 7.54-7.60 (m, 2H), 7.03-7.11 (m, 4H), 6.87-6 .93(m, 2H), 6.48(m, 2H), 6.27-6.31(dd, 1H), 6.16-6.19(dd, 1H), 5.80(s, 1H), 5.10-5.32(q, 2H), 4.57-4.5 9 (m, H), 4.42-4.45 (m, H), 3.93 (s, 3H), 3.80 (s, 3H), 3.68-3.71 (q, 2H), 3.66 (s, 3H), 3.41 (s, 3H), 3.24 (s, 3 H), 2.86-2.88(m, 2H), 2.42-2.63(m, 2H), 1.85-1.87(d, 3H), 1.68-1.72(t, 3H), 0.50(s, 1H), -1.67(s, 1H).

[0061] MS (ESI + )m / z:885.39[M+H] + (100%) Figure 2 ).

[0062] Comparison of infrared absorption spectra of PPA, Curcumin and PPA-Curcumin ( Figure 3 )

[0063] Example 2

[0064] Preparation of esterified conjugates of polycarboxyporphyrin and curcumin:

[0065] Preparation of mono- and di-substituted esterification products of protoporphyrin (PPIX) and curcumin:

[0066] After nitrogen was purged into the reaction flask, PPIX 56.3mg (0.1mmol), EDCI 48mg (0.25mmol), chloroform 15mL, tetrahydrofuran 5mL, DMAP 6mg (0.05mmol) were added, and the mixture was dispersed by ultrasound. The reaction was continued at room temperature and away from light for about 24h. It was observed that the reaction system was no longer turbid. 5mL of ethanol was added and the reaction was continued for about 30min. The solvent was evaporated under reduced pressure, dissolved with a small amount of dichloromethane, and 10 times the amount of petroleum ether was added for oscillation, and the crude product was obtained by suction filtration. The crude product was washed with 1% dilute hydrochloric acid and distilled water to remove residual DMAP and EDCI, and then washed with ethanol to remove unreacted curcumin. The obtained crude mass spectrometry showed ( Figure 4 ) mainly obtained compound I (PPIX-CC) and compound II (PPIX-CE), and the molecular structures are shown below.

[0067]

[0068] The above crude product was chromatographed on a silica gel column with a developing solvent volume ratio of dichloromethane:methanol = 35:1, and the red fluorescent chromatographic band was collected to obtain the main esterification product PPIX-CE, which accounted for about 60% (25 mg), while the esterification product PPIX-CC accounted for only 40% (17 mg).

[0069] Molecular structure characterization of the main product PPIX-CE:

[0070] 1H-NMR (400MHz, CDCl3, ppm, Figure 5)δ10.19(s, 1H), 10.13(d, 1H), 10.05(d, 1H), 10.05(s, 1H), 8.2-8.27(dd, 2H), 7.43 -7.54(m, 2H), 7.03-7.05(d, 1H), 6.97(s, H), 6.89(s, H), 6.85-6.89(t, 2H), 6.69-6. 71(m,H),6.30-6.40(m,4H),6.12-6.15(d,1H),5.7-5.79(d,1H),5.27-5.29(t,1H), 4.45-4.49(t, 2H), 4.29-4.33(t, 2H), 4.00-4.05(q, 2H), 3.87(s, 3H), 3.77-3.82(q,

[0071] H), 3.65-3.67(t, 6H), 3.56-3.62(dd, 6H), 3.50-3.54(t, 2H), 3.35(s, 3H), 3.13-3.16(t, 2H), 1.92-1.95(t, 3H), -3.68(s, 2H).

[0072] MS (ESI + )m / z:941.42[M+H] + (100%) Figure 6 ).

[0073] Application Examples

[0074] PPA-Curcumin was used as an example to evaluate the anti-tumor cell activity of the porphyrin and curcumin conjugate of the present invention. In this activity experiment of PPA-Curcumin against melanoma B16 cells, three groups were set up, namely a blank control group, raw material PPA, and product PPA-Curcumin. Three parallel experiments were conducted in each group, divided into two conditions: illumination and no illumination. The illumination condition was 670-680nm, and a 96-well LED light board (power 0.3W / cm 2 ), irradiation time 5min, and test drug concentration 1μM / L.

[0075]

[0076] Example 3

[0077] PPA-Curcumin Reactive Oxygen Species (ROS) Detection:

[0078] (1) The cultured melanoma B16 cells were inoculated into 24-well confocal imaging plates (a total of 2 plates, one for the illumination group and the other for the non-illumination group) at a density of 5×10 4cells / well, 500 μL per well, three parallel experimental groups, and incubated the plate for 12 hours to allow the cells to adhere.

[0079] (2) Remove the culture medium from each well, add 475 μL of new culture medium, and then add 25 μL of each drug according to the number, pipette evenly, and continue incubation for 24 hours.

[0080] (3) Discard the cell culture medium, add 1 mL of DCFH-DA working solution (10 μM / L), incubate in a dark incubator for 20 min, aspirate the staining solution, and wash with PBS.

[0081] (4) The illumination group was treated with 670-680 nm laser (0.3 W / cm 2 ) irradiate for 5 minutes.

[0082] (5) Finally, confocal fluorescence microscopy was used for imaging and qualitative analysis.

[0083] Example 4

[0084] In vitro activity test of PPA-Curcumin against melanoma B16 (cell live / dead staining analysis):

[0085] (1) The cultured melanoma B16 cells were inoculated into 24-well plates (confocal imaging special plates) (a total of 2 plates, an illumination group and a non-illumination group) at a density of 5×10 4 cells / well, 500 μL per well, and incubate for 12 hours.

[0086] (2) Remove the culture medium from each well, add 1 mL of new culture medium and 25 μL of the sample to be tested (concentration 20 μM / L), and continue culturing for 24 hours.

[0087] (3) The illumination group used a 670-680nm LED light panel (0.3W / cm 2 ) were irradiated for 5 min and incubated for 4 h.

[0088] (4) Staining was performed according to the instructions of the Calcein-AM / PI live cell / dead cell double staining kit.

[0089] (5) Live / dead imaging of melanoma B16 cells using confocal microscopy (green indicates live cells and red indicates dead cells).

[0090] Discussion on the experimental results of PPA-Curcumin anti-melanoma B16 cell activity:

[0091] By detecting the reactive oxygen species (ROS) and in vitro anti-melanoma B16 cell activity of PPA-Curcumin and PPA under 670-680nm laser irradiation, it was found that under the same conditions, the esterification coupling product PPA-Curcumin and the raw material PPA both had strong reactive oxygen production rates. Although PPA-Curcumin retained a reducing phenolic hydroxyl group of curcumin, it was found that the introduction of curcumin, which inhibits tumor cell proliferation and metastasis, did not significantly reduce the reactive oxygen production rate. Cell live-death experiments showed that both PPA-Curcumin and PPA had strong anti-melanoma photodynamic activity. Since photodynamic therapy can kill a large number of tumor cells in a short period of time, and curcumin's inhibition of tumors is time- and dose-dependent, curcumin can play an auxiliary role in PPA photodynamic anti-tumor therapy.

[0092] Therefore, the porphyrin and curcumin ester conjugate prepared by the present invention has practical application value in anti-tumor photodynamic therapy.

Claims

1. A carboxyl porphyrin-curcumin ester conjugate, characterized in that: It has a chemical structure of Formula 1, Formula 2, Formula 3, Formula 4, Formula 5 or Formula 6: Among them, R is selected from R1, R2, R3 and R4 are independently selected from H or and at least one of R1, R2, R3 and R4 is 2. The method for preparing a carboxyl porphyrin-curcumin esterification conjugate according to claim 1, characterized in that: The carboxyl-containing porphyrin-like compound is coupled with the phenolic hydroxyl group of curcumin through a Steglich esterification reaction to obtain the porphyrin-like compound; the carboxyl-containing porphyrin-like compound has a chemical structure of Formula 7, Formula 8, Formula 9, Formula 10, Formula 11 or Formula 12:

3. The method for preparing a carboxyl porphyrin-curcumin esterification conjugate according to claim 2, characterized in that: The conditions of the Steglich esterification reaction are: using 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride as a condensation agent, using 4-dimethylaminopyridine as a catalyst, and reacting at 15 to 25° C. for 12 to 36 hours.

4. The method for preparing a carboxyl porphyrin-curcumin esterification conjugate according to claim 3, characterized in that: The Steglich esterification reaction uses chloroform solvent or a mixed solvent of tetrahydrofuran and chloroform.

5. The method for preparing a carboxyl porphyrin-curcumin esterification conjugate according to claim 3, characterized in that: The relative amount of the condensing agent added is 2 to 3 times the carboxyl content of the carboxyl-containing porphyrin-like compound; The relative amount of the catalyst added is 0.4 to 0.6 times the carboxyl content in the carboxyl-containing porphyrin-like compound.

6. The use of a carboxyl porphyrin-curcumin ester conjugate according to claim 1, characterized in that: Used to prepare anti-tumor reagents combined with photodynamic therapy and chemotherapy.

Citation Information

Patent Citations

  • Ligand-functioned super-molecular nano-drug delivery system for treating tumor

    CN102961755A

  • Pheophorbide curcumin ester with photosensitive activity and preparation method and application thereof

    CN103224499A

  • Porphyrin-chrysin compounds and anti-tumor activity thereof

    CN109912607A

Cited By

  • Monoheterocycle substituted porphyrin derivative, preparation method thereof and application of monoheterocycle substituted porphyrin derivative as photosensitizer

    CN119912459A

  • Monoheterocyclic substituted porphyrin derivatives, preparation methods thereof, and use thereof as photosensitizers

    CN119912459B

  • Mono-heterocycle-substituted porphyrin derivative, preparation method therefor and use thereof as photosensitizer

    WO2026207681A1